Review of cervical cancer screening

Cervical cancer screening guidelines are undergoing revisions globally, with several European countries updating their protocols to incorporate human papillomavirus (HPV) testing starting at age 30 with a five-year interval, aligning with EU recommendations from 2015. Fujirebio highlights new technologies for screening and triage, including HPV genotyping, that are being evaluated to enhance the benefit-to-harm balance of screening programs. Improved risk stratification for HPV-positive women is essential to reduce unnecessary referrals for follow-up and treatment, with HPV genotyping offering insights into oncogenic risk associated with different genotypes.